Paper42940323PubMed
Resveratrol Ameliorates Hyperuricemia in Association with Remodeling of the Gut Microbiota-Metabolism Axis: An Integrated 16S rDNA Sequencing and Fecal Metabolomics Study.
Wang Y and 7 others. Foods, 2026.
Cite this record
ConductScience Library. Resveratrol Ameliorates Hyperuricemia in Association with Remodeling of the Gut Microbiota-Metabolism Axis: An Integrated 16S rDNA Sequencing and Fecal Metabolomics Study. Papers, record 42940323. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42940323
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Resveratrol Ameliorates Hyperuricemia in Association with Remodeling of the Gut Microbiota-Metabolism Axis: An Integrated 16S rDNA Sequencing and Fecal Metabolomics Study.
- Journal
- Foods
- Year
- 2026
- Publication types
- Journal Article
- Revised in PubMed
- 2026-10-28
Source PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
Grants5
Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.
| Grant, as the record writes it | Agency | Country | NIH project | Stated by |
|---|---|---|---|---|
| 202501AT070150 | Yunnan Province Science and Technology Department | PubMed | ||
| 202401AT070216 | Yunnan Province Science and Technology Department | PubMed | ||
| 202505AV340010 | Yunnan Province Science and Technology Department | PubMed | ||
| 2024J0512 | Yunnan Provincial Department of Education | PubMed | ||
| 202603AS090006 | Yunnan Province Science and Technology Department | PubMed |
Source PubMed
References67
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 31263284 | Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. | Nat Med | 2019 | https://conductscience.org/library/papers/31263284 | PubMed |
| 2 | 28089200 | Limitations of the Current Standards of Care for Treating Gout and Crystal Deposition in the Primary Care Setting: A Review. | Clin Ther | 2017 | https://conductscience.org/library/papers/28089200 | PubMed |
| 3 | 30531976 | Gut microbiome structure and metabolic activity in inflammatory bowel disease. | Nat Microbiol | 2019 | https://conductscience.org/library/papers/30531976 | PubMed |
| 4 | 41132832 | Bacteroi des fragilis-derived succinic acid promotes the degradation of uric acid by inhibiting hepatic AMPD2: Insight into how plant-based berberine ameliorates hyperuricemia. | Acta Pharm Sin B | 2025 | https://conductscience.org/library/papers/41132832 | PubMed |
| 5 | 33480266 | The gut microbiota as a target to control hyperuricemia pathogenesis: Potential mechanisms and therapeutic strategies. | Crit Rev Food Sci Nutr | 2022 | https://conductscience.org/library/papers/33480266 | PubMed |
| 6 | 32579811 | Effects of Allopurinol on the Progression of Chronic Kidney Disease. | N Engl J Med | 2020 | https://conductscience.org/library/papers/32579811 | PubMed |
| 7 | 8985016 | Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. | Science | 1997 | https://conductscience.org/library/papers/8985016 | PubMed |
| 8 | 22865646 | Antihyperuricemic and nephroprotective effects of resveratrol and its analogues in hyperuricemic mice. | Mol Nutr Food Res | 2012 | https://conductscience.org/library/papers/22865646 | PubMed |
| 9 | 36948133 | Protective effect of sodium butyrate on intestinal barrier damage and uric acid reduction in hyperuricemia mice. | Biomed Pharmacother | 2023 | https://conductscience.org/library/papers/36948133 | PubMed |
| 10 | 32541923 | Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. | Nat Rev Rheumatol | 2020 | https://conductscience.org/library/papers/32541923 | PubMed |
| 11 | 39874797 | Gut microbiota as a new target for hyperuricemia: A perspective from natural plant products. | Phytomedicine | 2025 | https://conductscience.org/library/papers/39874797 | PubMed |
| 12 | 33798500 | Gout. | Lancet | 2021 | https://conductscience.org/library/papers/33798500 | PubMed |
| 13 | 40650188 | Influence of Gut Microbiota-Derived Butyrate on Intestinal Uric Acid Excretion and Hyperuricemia Regulation by Cichorium intybus L. | Int J Mol Sci | 2025 | https://conductscience.org/library/papers/40650188 | PubMed |
| 14 | 34692558 | Network of Interactions Between Gut Microbiome, Host Biomarkers, and Urine Metabolome in Carotid Atherosclerosis. | Front Cell Infect Microbiol | 2021 | https://conductscience.org/library/papers/34692558 | PubMed |
| 15 | 38088975 | A dynamics association study of gut barrier and microbiota in hyperuricemia. | Front Microbiol | 2023 | https://conductscience.org/library/papers/38088975 | PubMed |
| 16 | 37478828 | Purine-ifying uric acid by gut microbes. | Cell Chem Biol | 2023 | https://conductscience.org/library/papers/37478828 | PubMed |
| 17 | 39829115 | The Gut Microbiome in Hyperuricemia and Gout. | Arthritis Rheumatol | 2025 | https://conductscience.org/library/papers/39829115 | PubMed |
| 18 | 32774692 | Update on the epidemiology, genetics, and therapeutic options of hyperuricemia. | Am J Transl Res | 2020 | https://conductscience.org/library/papers/32774692 | PubMed |
| 19 | 37279756 | Gut bacterial metabolism contributes to host global purine homeostasis. | Cell Host Microbe | 2023 | https://conductscience.org/library/papers/37279756 | PubMed |
| 20 | 36034697 | Gut microbiota remodeling: A promising therapeutic strategy to confront hyperuricemia and gout. | Front Cell Infect Microbiol | 2022 | https://conductscience.org/library/papers/36034697 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42940323
GET https://conductscience.org/api/papers/v1/42940323/references?page=2